
Foot-and-mouth disease: How a new Australian vaccine might help farmers
While the disease can infect other cloven-hoofed animals, such as sheep, cows are the worst hit.
The last outbreak in Australia was in 1872. But three years ago, foot-and-mouth arrived in Indonesia, triggering widespread alarm and new biosecurity measures.
If the virus made it to Australia, it would put livestock exports at real risk.
Graziers are also on edge about the Government's decision to open the door to beef imports from the United States.
When an outbreak is detected, authorities usually have to cull huge numbers of animals to prevent it from spreading.
But now another option is emerging – a new Australian mRNA vaccine able to be tailored to specific viral strains.
If the vaccine proves safe and effective, it could let authorities respond rapidly to any outbreak by vaccinating animals in a ring around any outbreak.
What's so bad about foot-and-mouth?
If foot-and-mouth disease entered Australia, it would devastate the export trade. Photo / Mark Mitchell
The virus that causes foot-and-mouth disease is extremely contagious.
Many other infectious animal diseases only spread between animals in close proximity, but this virus can spread through the air and survive on surfaces for a long time.
The widespread and persistent damage it does to animal health, milk output and fertility is enough to make it a real concern for big farming nations such as Australia.
Livestock exporters rely on Australia's status as a nation free of major animal diseases.
Listen to Australian correspondent, Chris Russell, talk to Jamie Mackay about the foot-and-mouth disease mRNA vaccine on The Country below:
This status means animals and animal products can be freely exported to many nations.
If foot-and-mouth entered Australia, it would devastate the export trade.
Many countries would stop buying Australian animals and animal products to stop the virus from getting into their own disease-free herds.
In 2001, an outbreak of the virus in the United Kingdom was detected after it had already spread widely.
To control it, authorities culled over six million animals.
It cost the industry an estimated A$16 billion ($17.5b) in damages.
These mass culls are done because the virus is so contagious.
Authorities have to race against its spread.
How would this vaccine fit in?
It's unlikely Australia's 30 million cattle would be pre-emptively vaccinated against the virus.
This is for several reasons.
While vaccines help animals fight the virus, pre-emptive vaccination could actually affect Australia's disease-free status, as vaccination can make it harder to detect an outbreak.
Immunity tends to last less than a year.
The virus has many different strains, which makes it harder to get full protection.
Any vaccine has to match the dominant strains in a region.
If foot-and-mouth got into Australia, the main goal would be to eradicate it as quickly as possible.
Otherwise, the virus could jump into feral herds of pigs, goats and deer, after which it would become very difficult to control.
If the virus were detected early and confined to a small area, authorities would most likely lock down animal movement in the area and slaughter the affected herds.
But if the virus was detected late and a wider outbreak was under way, authorities would have to launch a different response.
This would involve creating blockages to the virus as quickly as possible.
Vaccinating animals in the wider area would act to create a barrier to the virus spreading, alongside other measures such as restricting animal movement and culling.
Vaccines for foot-and-mouth aren't new.
Stockpiles already exist overseas, and Australia would be able to access these in the event of an outbreak.
There are two reasons this new mRNA vaccine is a significant development.
First, it's being locally produced, making it easier for authorities to ramp up a response at the speed required.
Second, mRNA technology offers the ability to rapidly tweak vaccines to match new strains.
This would likely boost how effective it is.
Production of mRNA vaccine can be scaled up very quickly, too.
While the technology seems promising, it's not guaranteed.
Livestock vaccines have to pass rigorous regulatory checks to ensure they're safe for the animals and for human consumers.
What's next?
The news of this new vaccine for foot-and-mouth is welcome. But it's not a silver bullet.
Australia has long relied on stringent biosecurity measures to protect its large agricultural export industries.
To boost their effectiveness, authorities have also rolled out new technologies such as one of the world's best livestock tracking systems.
Each cow in Australia has a unique ID tag.
The tag records where the animal has been over the course of its life.
If there's an outbreak of an infectious disease such as foot-and-mouth, this tracking data will be invaluable.
Authorities will be able to see where infected animals have been and which others may have been exposed.
Vaccines, culling and tracking might sound like overkill. But this simple virus cannot be underestimated.
Timothy J. Mahony, Professor of Animal Health and Director, Centre for Animal Science, The University of Queensland.
Disclosure statement: Timothy J. Mahony has worked on disease modelling and vaccine development for another livestock disease, lumpy skin disease. This project received financial support from the Queensland government's Department of Agriculture and Fisheries.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Techday NZ
14 hours ago
- Techday NZ
OneMRI raises AUD $2.5m to expand preventive MRI scan service
Australian startup OneMRI has raised AUD $2.5 million in seed capital to expand its national service offering preventive whole-body MRI scans for early detection of a wide range of health conditions. Funding round The seed round was oversubscribed, with participation from investors including OIF Ventures, TEN13, Antler, Salus Ventures, AfterWork Ventures, Archangel Ventures, Black Sheep Capital, Prtnr, Larsen Ventures, Tribe Global Ventures, as well as several clinicians and radiologists. The funding aims to support OneMRI's growth across Australia to meet increasing consumer interest in proactive health management. OneMRI was founded in October 2024 by Dr. Vu Tran and Andrew Barnes, known for their work at Go1, alongside entrepreneur Gopi Sara. The company markets itself as Australia's first and only national provider of whole-body MRI scans, designed to enable early detection of over 500 potential health conditions including cancers, metabolic disorders, benign growths, autoimmune conditions such as MS, spinal degeneration, and brain aneurysms. Preventive health model The clinical approach at OneMRI is supported by research and development, with scan reviews by radiologists and consultations with doctors to ensure clinical rigour. The scans are intended to complement, not replace, more targeted diagnostic tests. Gopi Sara, OneMRI Co-founder and Chief Executive Officer, described the firm's emphasis on an ethical and patient-focused process. "OneMRI's process is genuinely customer-centric, with a rigorous eligibility and informed consent framework. We have a duty of care to every individual, which is why thoughtful screening is at the core of our approach. Every appointment includes both a pre- and post-scan consultation with qualified clinicians and dedicated care coordinators - ensuring patients fully understand the process, their results and what potential next steps might look like." OneMRI partners with radiology providers such as Scan Medical and Pinnacle Medical Imaging, and collaborates with healthcare professionals and wellness brands including The Banyans, Evergreen Doctors, Melbourne Functional Medicine, and Longev. By partnering with underutilised clinics, the company utilises MRI machines operating below capacity without increasing strain on existing healthcare resources. Sector growth and patient access Dr. Vu Tran, Co-Founder and Head of Medical, OneMRI, highlighted the increasing relevance of preventive health and technology in the sector. "Wellness and preventive health are only going to grow as sectors - and technology will play a critical role in that evolution. Right now, radiology is one of the most underutilised tools in preventive care. The 'health curious' increasingly want autonomy, access, and answers. Individuals should have the agency to take a proactive approach to their health, and whole-body MRI scans are one of the safest ways to do that - offering a multi-system snapshot in a single, radiation-free investigation. Our aim is to increase OneMRI's footprint and accessibility through market growth and product innovation. We've already seen everyday Australians, from schoolteachers to nurses, benefit from our scans, and believe that we have an important part to play as more people take a proactive approach to their long-term health." Early adopters of the service have already identified previously undetected life-threatening conditions. Michelle, 49, a Life Coach from Sydney, commented on her reasons for participating: "I did a preventive MRI not out of fear, but because I believe in being proactive with my health. It gave me peace of mind and reminded me how important it is to listen to our bodies and take care of ourselves before something feels wrong." David Shein, Partner at OIF Ventures, remarked on the investment: "Investing in OneMRI is not only an exceptional opportunity to back a fast-growing sector, but it's also a way for us to support improved and more accessible care for Australians over time. I've been very impressed with what the team has achieved to date, and anticipate strong future growth for the company." Current operations and expansion OneMRI currently provides its services in Brisbane, the Gold Coast, Perth, Sydney, Newcastle, and Melbourne, with further locations expected to be added as expansion continues. The company is also preparing to offer its services across the Asia Pacific region in future international growth plans.


Scoop
a day ago
- Scoop
Faster, More Accurate Brain Tumour Diagnoses For Kiwis
Minister of Health More than 100 New Zealanders have already benefited from a groundbreaking diagnostic tool that is delivering faster, more accurate brain tumour diagnoses, Health Minister Simeon Brown says. DNA methylation profiling, the international gold standard for diagnosing brain tumours, has been rolled out at Auckland City Hospital over the past year. 'This technology is a game-changer for brain tumour diagnosis in New Zealand. It enables doctors to pinpoint the exact tumour type with greater precision and in less time, meaning patients can start the right treatment sooner,' Mr Brown says. 'Until now, diagnosis was typically made by microscopic examination. In some complex cases, samples were sent overseas for methylation profiling, but that could take up to six weeks. 'Having this cutting-edge capability in New Zealand means more Kiwi patients can access this advanced diagnostic technology locally. Turnaround times are faster, around four weeks, and quicker for urgent cases. 'It also means we can prioritise urgent cases, deliver answers sooner, and give patients and their families greater certainty.' In some recent cases done locally, methylation profiling has significantly altered the initial diagnosis. In others, it has identified rare or unexpected tumour types that may have been missed using traditional methods. The Auckland-based service is one of only three in Australasia, with samples from hospitals around the country also being sent to Auckland for analysis. Along with improving access and outcomes for patients, it is also significantly cheaper than sending samples offshore. 'Delivering faster access to cancer treatment is a key focus for the Government, which is why it is one of our five national health targets. Faster, more accurate diagnosis for brain tumours that may be cancerous is a vital part of that. 'By providing local access to the world's best diagnostic tools, we are improving outcomes for New Zealanders,' Mr Brown says.


NZ Herald
3 days ago
- NZ Herald
Bowel screening uptake in Bay of Plenty appalling
It is a similar story in the Lakes health district, covering Taupō and Rotorua, where 27,694 were sent between August 1, 2022, and May 26, 2025. Of those, only 15,039 were returned. These figures are alarming because New Zealand has one of the world's highest bowel cancer rates, and it is the second-highest cause of cancer. That means an average of about eight people a day are being told they have it. It's not just an older person's cancer either, because more than 350 people under 50 are diagnosed annually. Many people know someone who has survived bowel cancer or died from it, and much has been done over the past eight years to try to get in front of the problem. The National Bowel Screening Programme started in July 2017 and has been introduced by all the former 20 district health boards, with Bay of Plenty being the last. People are invited to join the programme at 60, and are then sent a free home-test kit every two years until the age of 74. The Government is lowering the eligibility age to 58 nationwide from March. It has, however, been criticised for axing plans to lower the age for Māori and Pacific people to 50. The national charity Bowel Cancer New Zealand wants the screening age lowered to match Australia, where it is 45. It is, understandably, unhappy with the Government's slow progress. The media and advertising also play important roles in raising awareness. There are countless news articles in the media, and the national bowel screening multimedia campaign launched in July 2022 encourages people to take part in screening, emphasising it is free, quick and simple, 'and you can do it at home'. The good news is that Health NZ credits the campaign with raising awareness. But perhaps among the most powerful weapons for raising awareness are the individual patient stories. Kiwis such as Tauranga survivor Rachael Ferguson, who was 32 when she was diagnosed with stage 4 bowel cancer in December 2020. She has been 'clear' since surgery in February 2021. Then there's Rotorua father Matthew Keogan, who was 49 when he was diagnosed in 2021. He was told to get his affairs in order and say goodbye to his family as he might live only another three to six months. He has made a miraculous recovery after chemotherapy and immunotherapy with pembrolizumab (Keytruda). Last month, Northland's Cheryl Waaka, a former Black Fern and mother of two teenagers, talked about facing her toughest opponent yet: stage 4 bowel cancer. There are plenty of other personal stories on Bowel Cancer NZ's website, each offering an insight into that person's journey, each offering hope and each helping drive a greater understanding. All these people are brave and inspirational. So, given there's been a national screening campaign, heightened awareness, personal stories, and a lowering of the screening age, a reasonable question remains: Why would people fail to do something simple that costs them nothing but could save their lives? Reasons could include fear, stigma and people simply not wanting to go through what they perceive as the unpleasant procedure of having to collect samples and send them off. However, it would be fair to say some people probably can't be bothered, are ignorant or believe it won't happen to them. Whatever the reasons, the Bay of Plenty and Lakes figures are appalling. As survivor Rachael Ferguson rightly says, there are 'so many people under the age of 60 that are screaming out to have those kits' that eligible people not returning them is simply 'wasted resources'. The Government needs to lower the screening age further. At the same time, everyone eligible needs to take up the offer. It could save their lives. Bowel Cancer NZ chief executive Peter Huskinson has the final word. 'That free test in your mailbox doesn't just detect cancer – it can stop it before it starts,' he says. 'Don't leave it in a drawer. Put it by the loo and get it done.' Wise words indeed. Sign up to the Daily H, a free newsletter curated by our editors and delivered straight to your inbox every weekday.